article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Dapagliflozin and Right Ventricular Pulmonary Vasculature in HFpEF

JAMA Cardiology

This randomized clinical trial investigates the effect of dapagliflozin on right ventricular performance and vascular load during exertion in heart failure with preserved ejection fraction (HFpEF).

article thumbnail

Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction

American College of Cardiology

The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).

article thumbnail

Right ventricular function and anemia in heart failure with preserved ejection fraction

Frontiers in Cardiovascular Medicine

The level of hemoglobin (Hb) had a weak negative linear correlation with NT-pro-BNP (log-transform, r = 0.30, P < 0.0001) and a positively correlation with the tricuspid annular plane systolic excursion (TAPSE)/pulmonary arterial systolic pressure (PASP) ratio (r = 0.44, P < 0.0001).

article thumbnail

Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium

European Journal of Heart Failure

The interplay of MR and HFpEF: understanding increased pulmonary pressures and strategies for management. HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. Abstract Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF).

article thumbnail

Top 10: Must-reads from the Month of May

DAIC

Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10. Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial 9. Tenax Therapeutics Announces New U.S.

article thumbnail

Right Ventricular?Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. Journal of the American Heart Association, Ahead of Print. TAPSE/PASP and TAS’/PASP can be useful parameters to detect PH in patients with HFpEF.